Dyne Therapeutics, Inc. DYN
Set alert
17.94 USD +0.63 +3.67%
As of Nov 3, 10:51 AM ET
17.32 Day range 18.00
14.00 52-week range 27.31
- YTD
- -8.31%
- 1 year
- -25.61%
- Open
- 17.53
- Prev close
- 17.30
- Mkt cap
- 3.35B
- Vol
- 411.08K
- Avg vol
- 2.78M
- EPS
- -3.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.32
- High
- 18.00
- Forward P/E
- -5.22
- Beta
- 1.21
- Short ratio
- 7.94
- Inst. own
- 103.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 18.53
- 200-d avg
- 19.31
- 1y target
- 34.33
1D chart
Signals (10)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 10:37 AM | 14 minutes ago |
| MACD: Buy Signal | 10:35 AM | 16 minutes ago |
| SMA: Bullish | 10:31 AM | 20 minutes ago |
| SMA: Bearish | 10:30 AM | 21 minutes ago |
| SMA: Bullish | 10:26 AM | 25 minutes ago |
| SMA: Bearish | 10:25 AM | 26 minutes ago |
| MACD: Sell Signal | 10:21 AM | 30 minutes ago |
| MACD: Buy Signal | 10:17 AM | 34 minutes ago |
| MACD: Sell Signal | 10:07 AM | 44 minutes ago |
| RSI: Overbought | 10:01 AM | 50 minutes ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.33 +91.4% upside
Now 17.94
- Target (low)
- 10.00
- Target (mean)
- 34.33
- Target (high)
- 50.00
Ratings (0m) 17 15 buy · 1 hold · 1 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.88189 | -1.09 – -0.65 | -0.76 | -16.0% | 0 | 0.0% | 14 |
| Next quarter | -0.90689 | -1.11 – -0.58 | -0.73 | -24.2% | 0 | 0.0% | 14 |
| Current year | -3.53 | -3.94 – -2.84 | -3.47 | -1.7% | 0 | 0.0% | 15 |
| Next year | -3.31 | -4.53 – -2.75 | -3.53 | +6.1% | 53.40M | 0.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Sep 30, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Sep 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 29, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 9, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 9, 2026 | JP Morgan | Downgrade | Neutral | Underweight |
| Sep 9, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 9, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 23, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 26, 2026 | TD Cowen | Initiated | — | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| Mar 9, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 3, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 20, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Dec 15, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 11, 2025 | Stifel | Maintained | Buy | Buy |
| Dec 10, 2025 | Oppenheimer | Upgrade | Perform | Outperform |
| Dec 9, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Dec 9, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Dec 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 12, 2025 | Oppenheimer | Maintained | Perform | Perform |
| Nov 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 6, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 10, 2025 | Oppenheimer | Downgrade | Outperform | Perform |